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Replenishing insulin-producing pancreatic b cell
mass will benefit both type I and type II diabetics.
In adults, pancreatic b cells are generated primarily
by self-duplication. We report on a mouse model of
insulin resistance that induces dramatic pancreatic
b cell proliferation and b cell mass expansion. Using
this model, we identify a hormone, betatrophin, that
is primarily expressed in liver and fat. Expression of
betatrophin correlates with b cell proliferation in
other mouse models of insulin resistance and during
gestation. Transient expression of betatrophin in
mouse liver significantly and specifically promotes
pancreatic b cell proliferation, expands b cell mass,
and improves glucose tolerance. Thus, betatrophin
treatment could augment or replace insulin injections
by increasing the number of endogenous insulin-pro-
ducing cells in diabetics.INTRODUCTION
Diabetes results from dysfunctional carbohydrate metabolism
that is caused by a relative deficiency of insulin. It has
become a major threat to human health, the prevalence of
which is estimated to be 2.8% worldwide (171 million
affected) and is predicted to rise to 4.4% (366 million) by
2030 (Wild et al., 2004). Around 10% of diabetics in the United
States have type I diabetes, a disease caused by an autoim-
mune attack on pancreatic b cells and a consequent b cell
deficiency. The majority of diabetics are type II, characterized
by interrelated metabolic disorders that include decreased b
cell function, peripheral insulin resistance, and, eventually, b
cell failure and loss or dedifferentiation (Scheen and Lefe`bvre,
1996; Talchai et al., 2012). Though the disease can be treated
with antidiabetic drugs or subcutaneous insulin injection,
these treatments do not provide the same degree of glycemic
control as functional pancreatic b cells and do not prevent the
debilitating consequences of the disease. Treatments that
replenish b cell mass in diabetic patients could allow for the
long-term restoration of normal glycemic control and thus
represent a potentially curative therapy. Despite the fact that
the primary causes for type I and type II diabetes differ, all di-abetics will benefit from treatments that replenish their b
cell mass.
Though there is evidence that mouse b cells can be derived
from rare adult progenitors under extreme circumstances (Xu
et al., 2008), the vast majority of new b cells are generated by
simple self-duplication (Dor et al., 2004; Meier et al., 2008;
Teta et al., 2007). After a rapid expansion in embryonic and
neonatal stages, b cells replicate at an extremely low rate
(<0.5% divide per day) in adult rodents (Teta et al., 2005) and
in humans (Meier et al., 2008). However, pancreatic b cells retain
the capacity to elevate their replication rate in response to phys-
iological challenges, including gestation (Parsons et al., 1992;
Rieck et al., 2009), high blood sugar (Alonso et al., 2007), pancre-
atic injury (Cano et al., 2008; Nir et al., 2007), and peripheral in-
sulin resistance (Bru¨ning et al., 1997; Kulkarni et al., 2004;
Michael et al., 2000; Pick et al., 1998).
The genetic mechanisms controlling b cell proliferation are
incompletely understood. The cell-cycle regulators cyclin D1/
D2 and CDK4 promote b cell proliferation (Georgia and Bhushan,
2004; Kushner et al., 2005; Rane et al., 1999), and cell-cycle-
related transcription factors such as E2F1/2 are essential for
pancreatic b cell proliferation (Fajas et al., 2004; Iglesias et al.,
2004). On the contrary, cell-cycle inhibitors, including p15Ink4b,
p18Ink4c, and p27Kip1, repress b cell replication (Latres et al.,
2000; Pei et al., 2004; Uchida et al., 2005). Other genes reported
to regulate b cell proliferation include NFAT, Menin, p53, Rb, and
Irs2 (Crabtree et al., 2003; Harvey et al., 1995; Heit et al., 2006;
Kubota et al., 2000; Williams et al., 1994).
In addition to the factors listed above, which are expressed
in b cells themselves and act in a cell-autonomous fashion,
there are several reports showing that systematic or circu-
lating factors can regulate b cell replication and mass.
Glucose itself is a b cell mitogen; infusion of glucose in ro-
dents causes a mild increase in b cell replication (Alonso
et al., 2007; Bernard et al., 1998; Bonner-Weir et al., 1989).
And glucokinase defects significantly decrease the compensa-
tory proliferation of pancreatic b cells in some contexts (Terau-
chi et al., 2007). In addition, genetic deletion of glucokinase in
b cells can reduce replication rates, whereas pharmacological
activation of this enzyme increases replication by 2-fold (Porat
et al., 2011). Several hormones, including insulin, placental
lactogen, and prolactin, also play a role in regulating b cell
mass (Bernard et al., 1998; Paris et al., 2003; Parsons et al.,
1992; Sachdeva and Stoffers, 2009). The incretin hormones
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insulinotropic peptide (GIP) increase insulin secretion and pro-
mote b cell replication (reviewed in Drucker, 2006). However,
from a therapeutic perspective, the problem with manipulating
most of the genes and hormones currently known to impact b
cell replication is their lack of b cell specificity and/or the fact
that the magnitude of their effect on b cell proliferation is quite
modest.
Transplantation studies in mice have shown that insulin resis-
tance results in a circulating islet cell growth factor that is inde-
pendent of glucose and obesity (Flier et al., 2001). In a telling
demonstration, the liver-specific deletion of the insulin receptor
results in a dramatic compensatory increase in pancreatic b
cell replication (Michael et al., 2000). Similarly, overexpression
of a constitutively active MEK1 kinase in mouse liver increases
the replication rate in pancreatic b cells and improves glucose
tolerance in disease models through an innervation-dependent
mechanism (Imai et al., 2008). Precisely how the liver signals
pancreatic b cells to proliferate is unknown, but recent work by
Kulkarni’s group points to the possibility that liver cells secrete
a protein that acts directly on islet cells (El Ouaamari et al.,
2013; Flier et al., 2001).
In this study, we aimed to identify secreted signals that control
pancreatic b cell proliferation. As a first step, we developed a
novel insulin resistance mouse model in which b cell replication
can be rapidly induced at will. We show that administration of
an insulin receptor antagonist induces acute peripheral insulin
resistance and leads to a dramatic proliferation in pancreatic b
cells and subsequent b cell mass expansion. Using this model,
we identified a gene encoding a secreted protein that is ex-
pressed in liver and fat and whose expression level is elevated
upon insulin resistance. We called this gene betatrophin
because its overexpression in mouse liver produces a secreted
protein that significantly and specifically promotes pancreatic b
cell proliferation and b cell mass expansion and, consequently,
improves glucose tolerance.
RESULTS
Administration of an Insulin Receptor Antagonist
Induces Insulin Resistance and Pancreatic b Cell
Proliferation
Previous work showed that, when the insulin pathway is
blocked in vivo in the liver, pancreatic b cell mass expands
and there is an increase in insulin secretion as a compensatory
response (Bru¨ning et al., 1997; Michael et al., 2000). To inves-
tigate the signals that control this type of b cell compensatory
growth, we explored a new pharmacological model of severe
insulin resistance. S961 is a peptide (43aa) that binds the insu-
lin receptor and antagonizes insulin signaling both in vitro and
in vivo in rats (Scha¨ffer et al., 2008). We used osmotic pumps
to infuse adult mice with various doses of S961. The data in
Figure 1A show that S961 causes hyperglycemia in a dose-
dependent manner. A high dose of S961 infused for a week
makes the mice glucose intolerant (Figures 1B and 1C), consis-
tent with the fact that S961 blocks the insulin receptor. Plasma
insulin levels rise at all doses of the insulin antagonist, presum-
ably due to the compensatory effort of pancreatic b cells
(Figure 1D).748 Cell 153, 747–758, May 9, 2013 ª2013 Elsevier Inc.To examine whether S961 induces a compensatory b cell pro-
liferation, as seen in other insulin resistance models, the b cell
proliferation rate was analyzed by Ki67 and insulin immunofluo-
rescence for all dosage groups following S961 treatment. S961
treatment results in a dramatic increase in b cell proliferation
(Figure 2A), which is both immediate and dose dependent (Fig-
ure 2B and Figures S1A–S1E available online). The effect of
S961 on b cell replication rates is strong but transient: 4 days af-
ter S961 is withdrawn, b cell replication rates return to normal
(Figure S1F). The proliferation in b cells was confirmed by immu-
nostaining for a nuclear b cell marker (Nkx6.1) and a different cell
division marker (PCNA; Figures S2A and S2B). Quantitative PCR
analysis of cell-cycle regulators shows that, in pancreatic islets
following S961 treatment, the expression level of several cyclins
(cyclins A1, A2, B1, B2, E1, and F), CDKs (CDK1 and CDK2), and
E2Fs (E2F1 and E2F2) increases, whereas the expression of cell-
cycle inhibitors (Cdkn1a, Cdkn1b, and Cdkn2b) decreases (Fig-
ure S3A). Even a low dose of S961 (5 nmol/week), which does not
detectably alter blood glucose levels, produces a modest but
reproducible increase in b cell replication (4.3-fold increase;
Figure 2B). At the highest dose tested, S961 treatment resulted
in an 12-fold increase in b cell replication (Figure 2B), a rate
that vastly exceeds any previously reported pharmacological
treatment.
The increase in b cell replication rate appears to affect all
pancreatic islets equally (Figure S3B) and leads to an increase
in total b cell area of 3-fold within 1 week (Figures 2C–2E), pri-
marily resulting from an increase in islet size (Figure S3C).
Though b cell mass expands after S961 treatment, pancreatic in-
sulin content decreases (Figure 2F) possibly because b cells
secrete more of their insulin into circulation as a consequence
of insulin resistance. And though treatment of mice with a low
dose of S961 (2.5 nmol/week) does not produce a detectable in-
crease in b cell proliferation at day 7, as measured by Ki67 (Fig-
ure 2B), their b cell mass is nonetheless about 1.5-fold higher
than the control. Quantification of average b cell size shows no
significant difference between vehicle- and S961-treated ani-
mals (Figure S3D). Thus, the increased b cell mass observed at
the low dose of S961 (2.5 nmol/week) is not likely due to b cell
hypertrophy but, rather, to the result of a transient increase of
b cell proliferation prior to day 7 of S961 treatment. The prolifer-
ation induced by S961 administration is highly specific to
pancreatic b cells. No obvious differences in cell proliferation
rates were noticed between control- and S961-treated animals
for other pancreatic cell types, including other endocrine cells,
exocrine cells, and duct cells, nor for liver, white fat, or brown
fat (Figure 2G).
Identification of Betatrophin in S961-Treated Mouse
Liver and White Fat
To understand how S961 induces b cell proliferation, we first
applied it directly to mouse b cells in vitro to see whether this in-
sulin antagonist works in a b-cell-autonomous manner, but there
was no detectable effect (data not shown). Based on this result,
we hypothesized that S961 acts indirectly on b cells and
analyzed gene expression in tissues involved in metabolic regu-
lation (liver, white fat, and skeletal muscle) in addition to pancre-
atic b cells themselves to identify potential mediators of the
Figure 1. Administration of the Insulin Receptor Antagonist S961 Induces Glucose Intolerance, Hyperglycemia, and Hyperinsulinemia
(A) Continuous treatment of male C57BL/6J mice for 7 days with S961 at different dosages induces hyperglycemia. The fed glucose level is measured daily after
pump implantation. n = 4 for each dosage group.
(B) Glucose tolerance test at the end of a 1 week treatment with S961 (10 nMol/week) shows glucose intolerance. n = 4 for each group.
(C) Area under curve (AUC) for the glucose tolerance test shown in (B).
(D) Continuous treatment of S961 by an osmotic pump at different doses induces hyperinsulinemia. n = 4 for each dosage group.
*p < 0.05 and **p < 0.005 compared to vehicle treatment. Data are represented as mean ± SEM.effect. Microarray analysis pointed to one gene, which we call
betatrophin (Figure 3A). Betatrophin is upregulated in S961-
treated liver (4-fold) and white fat (3-fold), but its expression
is unchanged in skeletal muscle and in pancreatic b cells (Fig-
ure 3B) in response to S961.
Betatrophin encodes a predicted protein of 198 amino acids
(the mouse gene was previously annotated as Gm6484 and the
protein as EG624219; the human gene is annotated as
C19orf80 and the protein hepatocellular carcinoma-associated
protein TD26 [Dong et al., 2004]). The gene has four exons and
lies within the intron of another gene, Dock6, on the opposite
strand (Figure S4A). Betatrophin is highly conserved in all
mammalian species examined (Figure S4B) but evidently absent
in nonmammalian vertebrates and in invertebrates (data not
shown).Betatrophin Is Enriched in Liver and in Fat Tissues, and
Its Expression Correlates with High Pancreatic b Cell
Proliferation Rates
Betatrophin mRNA is expressed in mouse liver and fat, with min-
imal expression in other tissues examined (Figure 3C), consistent
with previous reports (Quagliarini et al., 2012; Ren et al., 2012;
Zhang, 2012). In humans, betatrophin is primarily expressed in
the liver (Figure 3D), where betatrophin mRNA levels are >250-
fold higher than that found in other tissues tested. Betatrophin
protein can also be detected by western blotting in human liver
(Figure 4J).
To determine whether betatrophin might be involved in
regulating b cell replication in other contexts, we examined beta-
trophin mRNA expression by quantitative PCR in several physi-
ologically relevant animal models of increased b cell replication.Cell 153, 747–758, May 9, 2013 ª2013 Elsevier Inc. 749
Figure 2. Administration of the Insulin Receptor Antagonist S961 Induces Pancreatic b Cell Proliferation and b Cell Mass Expansion
(A) S961 infused into adult mice at 10 nMol/week for 1 week induces pancreatic b cell proliferation (shown by costaining of Ki67 and insulin).
(B–E) (B) Proliferation rates of pancreatic b cells measured as percentage of dividing b cells 7 days after S961 treatment at different doses. S961 treatment
significantly increases b cell area shown by insulin immunohistochemistry (brown) (representative sections shown in C and D; b cell area as a percentage of total
pancreas area in E). n = 4 in each dosage group.
(F) Total pancreatic insulin content (normalized by total protein content) in vehicle-treated or S961-treated (10 nMol/week) mice. n = 3 in each group.
(legend continued on next page)
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Figure 3. Identification and Expression of Betatrophin
(A) Microarray analysis of livers (n = 4 for each group) following 1week S961 (10 nMol/week) or vehicle treatment. Candidate genes with at least a 3-fold difference
compared to control were chosen. The red dot is betatrophin.
(B) Relative expression of betatrophin mRNA by microarray analysis in liver, white fat, skeletal muscle, and b cells in S961-treated (10 nMol/week) versus vehicle-
treated mice (1 week treatment). n = 4 in each group except S961 treated b cells, in which n = 3 (normalized by average RNA expression level in each sample).
(C) Relative expression of betatrophin by real-time PCR analysis in mouse organs/tissues, normalized by total RNA input.
(D) Relative expression of betatrophin by real-time PCR analysis in various human tissues, normalized by total RNA input.
(E) Real-time PCR analysis of betatrophin in liver andwhite fat samples fromS961-treated (10 nMol/week) or vehicle-treated mice (7 days treatment). n = 5 in each
group.
(F andG) (F) Livers fromC57BL/6J (n = 4), ob/ob (n = 4), and db/db (n = 4) malemice and (G) livers fromC57BL/6J female mice at different gestational stages (n = 3
in each group). Dpc, date postconception.
*p < 0.05 and ** p < 0.005 compared to vehicle treatment or wild-type animals. Data are represented as mean ± SEM. See also Figure S4.Infusion of the insulin receptor antagonist S961, which causes a
dramatic pancreatic b cell proliferation, leads to a 6-fold upregu-
lation of betatrophin in liver and 4-fold in white fat (Figure 3E),
consistent with the microarray analysis (Figure 3B). In mouse
models of type II diabetes, there is increased pancreatic b cell
mass (Bock et al., 2003; Gapp et al., 1983; Tomita et al., 1992;
Wang and Brubaker, 2002), and betatrophin mRNA is upregu-
lated 3- to 4-fold in the liver of both ob/ob and db/db mice (Fig-
ure 3F). b cell replication rates also increase during pregnancy
(Karnik et al., 2007), and expression of betatrophin mRNA in
the liver increases by 20-fold over the course of gestation (Fig-
ure 3G). Finally, specific depletion of b cells with diphtheria toxin
leads to increased b cell replication (Nir et al., 2007). This treat-
ment did not stimulate changes in betatrophin mRNA expression
in the liver (data not shown). Together, these results indicate that
betatrophin expression may contribute to compensatory(G) Replication rates are measured as percentage of cells staining for Ki67 an
endocrine cells (Gcg+Sst+Ppy), exocrine cells, and pancreatic duct cells as well
tissue [BAT]) after treatment of S961(10 nMol/week) or vehicle treatment. n = 5 f
*p < 0.05 and **p < 0.005 compared to vehicle treatment. Data are representedpancreatic b cell proliferation as a response to physiological
challenges, but not as a regeneration response after acute injury.
Betatrophin Encodes a Secreted Protein
How might a protein produced in the liver and fat cause pancre-
atic b cells to divide? Sequence analysis of mouse and human
betatrophin shows a predicted secretion signal at the N terminus
and two coiled-coil domains (Figure 4A). To demonstrate that
betatrophin is indeed a secreted protein, expression plasmids
encoding mouse and human betatrophin, fused with a Myc tag
at their C termini (referred to asmbetatrophin-Myc and hbetatro-
phin-Myc), were prepared and used to transfect tissue culture
cells and to express betatrophin in mouse liver by hydrodynamic
tail vein injection (Song et al., 2002; Yant et al., 2000; Zhang et al.,
1999). Ectopic gene expression in the cell line Hepa1-6 and in
liver cells in vivo shows Myc-tagged betatrophin protein ind are shown as fold increase over vehicle treatment. b cells (Ins), non-b-cell
as liver, white fat (white adipose tissue [WAT]), and brown fat (brown adipose
or each dosage group.
as mean ± SEM. See also Figures S1, S2, and S3.
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Figure 4. Betatrophin Encodes a Secreted Protein
(A) Predicted domains of the betatrophin protein.
(B and C) (B) Cellular localization of mbetatrophin-Myc or (C) hbetatrophin-Myc protein when transfected into the liver cell line Hepa1-6.
(D and E) (D) Cellular localization of mbetatrophin-Myc or (E) hbetatrophin-Myc when overexpressed in mouse liver through hydrodynamic tail vein injection.
(F and G) Western blots show (F) mbetatrophin-Myc protein or (G) hbetatrophin-Myc in the supernatant following gene transfection into 293T cells. GFP gene
transfection and the intracellular GAPDH protein are used as controls.
(H and I) Western blots show (H) mbetatrophin-Myc (I) or hbetatrophin-Myc protein in plasma (3 days after injection) when the gene is overexpressed in mouse
liver by hydrodynamic tail vein injection. GFP gene injection is the negative control.
(J) Western blot of human betatrophin in human liver and plasma samples. Cell lysate of hbetatrophin-Myc-transfected 293T cells is the positive control, and cell
lysate of GFP-transfected 293T cells is the negative control.vesicle-like structures, as expected for a secreted protein
(mouse, Figures 4B and 4D; human, Figures 4C and 4E). Myc-
tagged betatrophin protein is detected in the supernatant of
transfected of 293T cells as well as plasma from mice injected
with the expression plasmids (mouse, Figures 4F and 4H; hu-
man, Figures 4G and 4I). Betatrophin can be detected in human
plasma, demonstrating that endogenous betatrophin is a
secreted protein in vivo (Figure 4J).
Expression of Betatrophin in Liver InducesDramatic and
Specific Pancreatic b Cell Proliferation and Improves
Glucose Tolerance in Mice
To determine whether betatrophin can promote pancreatic b
cell proliferation, we used hydrodynamic injection to deliver be-752 Cell 153, 747–758, May 9, 2013 ª2013 Elsevier Inc.tatrophin expression constructs to the liver, one of the normal
sites of betatrophin expression. Following injection, 5%–10%
of liver cells expressed betatrophin (or the control protein,
GFP; Figure S5), and this expression persisted for at least
8 days (data not shown). Injection of plasmids encoding beta-
trophin produces a striking increase in b cell replication (Fig-
ure 5A). The b cell proliferation rate in betatrophin-injected
animals averaged 4.6%, 17-fold higher than the control (GFP-
injected) rate of 0.27% (Figure 5B), with some individual ani-
mals achieving replication rates as high as 8.8% (33-fold
increase). The increased proliferation in b cells in betatrophin-
injected animals was confirmed by immunostaining for the b
cell nuclear marker Nkx6.1 and another cell division marker
(PCNA; Figures S2C and S2D). Similar to S961-treated mice,
quantitative PCR analysis also shows that the expression levels
of cyclins (cyclins A1, A2, B1, B2, D1, D2, and F), CDKs (CDK1
and CDK2), and E2Fs (E2F1 ad E2F2) increase, whereas cell-
cycle inhibitors (Cdkn1a and Cdkn2a) decrease in islets of
betatrophin-injected mice compared to control-injected mice
(Figure S3E). The increase in b cell proliferation was observed
in all islets examined (Figure S3F). The increased rate of prolif-
eration is so dramatic that one can easily identify islets and b
cells at low magnification simply by the immunostaining for
replication (Ki67; Figure 5C).
The high b cell proliferation rate in betatrophin-injected mice
leads to a significant expansion of b cell numbers and total
pancreatic b cell mass (Figure 5D). After 8 days, the total pancre-
atic b cell area in betatrophin-injected mice is 3-fold higher than
in control-injected mice (Figure 5E). This increase is the result of
having more b cells, which in turn increases islet size (Fig-
ure S3G). The total pancreatic insulin content also increases
(2-fold) in betatrophin-injected mice (Figure 5F).
The stimulation in replication caused by betatrophin expres-
sion is largely specific for b cells. As shown in Figure 5C and
5G, there is little if any effect on replication in other pancreatic
cell types (exocrine, ductal, and non-b-cell endocrine cells) or
in other organs (liver, white fat, and brown fat) (Figure 5G).
To evaluate b cell function, we isolated pancreatic islets
from control- or betatrophin-injected mice and performed a
glucose-stimulated-insulin-secretion (GSIS) analysis. As shown
in Figure S6, the GSIS of pancreatic islets from betatrophin-
injected mice is indistinguishable from control-GFP-injected
mice, suggesting that the normal function of b cells was
maintained after the b cell proliferation in betatrophin-injected
animals. In addition, a glucose tolerance test was performed
in control and betatrophin-injected mice. Mice were fasted
for 6 hr before glucose injection, and the data show that
betatrophin-injected mice have a lower fasting glucose level
(Figure 6A) and improved glucose tolerance compared to
control-injected mice (Figure 6A and as shown by area under
curve [AUC] in Figure 6B). Betatrophin expression also results
in a minor increase in fasting plasma insulin levels (Figure 6C),
possibly due to the relative short fasting time or an increased
glucose sensitivity.
Because insulin resistance is a potent stimulus known to
induce b cell proliferation, it is formally possible that betatro-
phin may act by first inducing insulin resistance, which in
turn leads to compensatory b cell proliferation by some other
mechanism. This possibility seems unlikely, as the lower fasting
glucose in mice overexpressing betatrophin is inconsistent with
an insulin-resistant phenotype. Nonetheless, to rule out this
possibility, we performed an insulin tolerance test and found
no difference between betatrophin- and control-injected mice,
in contrast to S961 administration (10nMol/week), which
produces a strong insulin resistance (Figure 6D). These data
show that betatrophin promotes b cell replication without
insulin resistance.
DISCUSSION
The possibility that the liver produces a signal for b cell prolifer-
ation has been suggested before, perhaps most convincingly byKahn’s work on the LIRKO mouse, a liver-specific depletion of
the insulin receptor that produces b cell hyperplasia (Michael
et al., 2000). Here, using a different method, we show that an in-
sulin receptor antagonist (S961) provides a chemical means of
achieving this same phenotype. In a dose-dependent manner,
provision of S961 induces a rapid and significant increase in b
cell replication and islet growth.
The S961 insulin resistance model enabled us to identify beta-
trophin. There are three recent reports in which the Gm6484/
TD26 gene was identified as a liver- and fat-enriched gene.
Those authors pointed to a possible lipoprotein lipase inhibition
activity or an effect on serum triglyceride regulation (Quagliarini
et al., 2012; Ren et al., 2012; Zhang, 2012) but did not report
any effects on pancreatic b cell biology, carbohydrate meta-
bolism, or diabetes. Our findings on betatrophin suggest that
this hormone can regulate metabolism by increasing insulin pro-
duction via an increase in b cell mass.
The upregulation of betatrophin observed during pregnancy
and in the ob/ob and db/db diabetic mouse models may explain
how b cell proliferation and b cell mass are expanded in those cir-
cumstances. In other genetic manipulations that increase b cell
replication, such as LIRKO and MEK1 mutations (Imai et al.,
2008; Michael et al., 2000), it remains to be determined whether
betatrophin is similarly upregulated.
The stimulation of b cell replication that we report with S961
and following injection of betatrophin DNA is noteworthy for the
rapidity and magnitude of the effect. b cell replication rate is
elevated 4-fold during gestation (Karnik et al., 2007), 2- to
4.5-fold with high glucose infusion (Alonso et al., 2007), 2.6-
fold with exendin-4 treatment (Xu et al., 1999), 4-fold in a b
cell ablation model (Nir et al., 2007), and 6-fold in LIRKO
mice (Okada et al., 2007). S961 treatment can increase b cell
replication by 12-fold, and providing betatrophin by DNA injec-
tion increased replication by an average of 17-fold within a few
days, making this an exceptionally potent activity. Together,
these results point to the importance of making recombinant
betatrophin protein and testing it directly by injection for effects
on b cell mass.
We do not yet know themechanism of action for betatrophin. It
may act directly or indirectly on b cells to control their prolifera-
tion. Identification of the betatrophin receptor and/or other
possible cofactors will help to explain how the liver and fat
interact with the pancreas to regulate b cell mass. Nonetheless,
identification of betatrophin as a hormone that can exert control
on b cell replication and b cell mass opens a newdoor to possible
diabetes therapy.EXPERIMENTAL PROCEDURES
Reagents and Mice
C57BL/6J, ob/ob, and db/db male mice at 8 weeks of age were purchased
from Jackson Laboratory. C57BL/6J female mice at 8 weeks of age were ob-
tained from Jackson Laboratory, fertilized, and timed to certain gestational
dates in house. For hydrodynamic tail vein injection, ICR male mice at 7 weeks
of age were purchased from Taconic. The Hepa1-6 cell line was obtained from
ATCC. To make expression plasmids for the GFP control or betatrophin,
cDNAs were amplified using PCR from a GFP expression plasmid or mouse/
human liver total RNA and subcloned into pT3-EF1a-DEST vector (a sleeping
beauty transposon vector) or pCAG-DEST vector. mbetatrophin is mouse, andCell 153, 747–758, May 9, 2013 ª2013 Elsevier Inc. 753
Figure 5. Overexpression of Betatrophin in the Liver Leads to a Specific Pancreatic b Cell Proliferation
(A) Expression of betatrophin in mouse liver by hydrodynamic tail vein injection of mbetatrophin-myc DNA strongly stimulates b cell replication compared to the
similarly injected control (DNA-encoding GFP).
(B) Quantification of the Ki67+/insulin+ ratio shows that betatrophin-injectedmice (n = 7) have a 17-fold higher rate of b cell replication compared to controls (GFP,
n = 5).
(legend continued on next page)
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Figure 6. Overexpression of Betatrophin in
the Liver Leads to Improved b Cell Function
(A) Glucose tolerance test in GFP-expressing (n =
5) or betatrophin-expressing (n = 7) mice shows a
lower fasting blood glucose and an improved
glucose tolerance induced by betatrophin
expression.
(B) Area under curve (AUC) for the glucose toler-
ance test shown in (A).
(C) Fasting plasma insulin measurement in GFP
(n = 5) or betatrophin (n = 7).
(D) Insulin tolerance tests on GFP-expressing
(n = 5) or betatrophin-expressing (n = 4) mice show
no sign of insulin resistance, in contrast to S961-
treated (10 nMol/week) animals (n = 5), which show
severe insulin resistance.
*p < 0.05 and **p < 0.005 compared to control-
injected animals. Data are represented as mean ±
SEM. See also Figure S6.hbetatrophin is the human gene. pT3-EF1a-DEST and the transposase-en-
coding plasmid pCMV-SB100 were gifts from Dr. Aaron Tward. Human
RNA, protein, and plasma samples were purchased from BioChain.
S961 Treatment
S961 was received as a generous gift from Dr. Lauge Scha¨ffer (Novo Nordisk)
(Scha¨ffer et al., 2008). Vehicle (PBS) or 2.5 nMol—10 nmol S961 was loaded
into Alzet osmotic pump 2001 and implanted subcutaneously on the back of
mice.
Total Insulin Content Measurement
To measure total insulin content, whole pancreata were dissected and pro-
cessed according to a standard acid-ethanol extraction protocol. The insulin
concentration of the extracts was determined usingMouseUltrasensitive Insu-
lin ELISA Jumbo (ALPCO). The total protein concentration was measured us-
ing a protein assay kit from Bio-Rad.
In Vitro GSIS Analysis
Pancreatic islets were isolated after infusion and digestion of the pancreata by
collagenase P (Roche). The islets were cultured overnight to recover in
RPMI1640+10% FBS media. About 20 size-matched islets from each mouse
were used for the in vitro GSIS assay. After fasting the islets in low-glucose
buffer (2.5 mM) for 2 hr, islets were washed and sequentially incubated with
400 ml of low-glucose buffer (2.5 mM), high-glucose buffer (15 mM), and(C) Two representative low-magnification images of pancreatic sections frommice injected with plasmids enc
replicating cells (Ki67) seen as white dots; the outline of the b cell area is based on insulin staining (not shown
exocrine tissue.
(D) Expansion of b cell area in mice expressing betatrophin compared to GFP controls, as shown by insulin
(E) Quantification of b cell area/total pancreas area in mice injected with betatrophin (n = 7) or control plasm
(F) Total pancreatic insulin content (normalized by total protein content) in GFP- or betatrophin-injected mice
group.
(G) The replication rates (fold over GFP control) in pancreatic b cells (Ins+), non-b-cell endocrine cells (Gcg+
liver, white fat, and brown fat after betatrophin injection (n = 5) or GFP injection (n = 5).
*p < 0.05 and **p < 0.005 compared to control-injected animals. Data are represented as mean ± SEM. See
Cell 153, 747then low-glucose buffer (2.5 mM) with 30 mM
KCl. These buffers were collected after incubation
and analyzed using the Mouse Ultrasensitive Insu-
lin ELISA Jumbo (ALPCO). Total genomic DNA
was extracted from all islets after the GSIS using
DNeasy blood and tissue kit (QIAGEN), and the
concentration of the genomic DNA was measuredusing a nanodrop. The insulin content measurement for each sample was
normalized to the total genome DNA content.
Immunohistochemistry
Mouse pancreata, liver, and brown fat were fixed in 4% paraformaldehyde for
2 hr at 4C. The white fat was fixed overnight. Cryosections (10–20 mm) were
pretreated with citrate buffer for antigen retrieval according to standard pro-
tocols and were immunostained with Guinea pig anti-insulin antibody (Dako),
mouse anti-Nkx6.1 antibody (DHSB), rabbit anti-Amylase antibody (Sigma),
rabbit anti-CK19 antibody (Abcam), rabbit anti-pancreatic polypeptide anti-
body (Abcam), rabbit anti-glucagon antibody (Cell Signaling), goat anti-
somatostatin antibody (Santa Cruz), and/or rat anti-Ki67 antibody (Dako),
rabbit anti-Ki67 antibody (Abcam), and mouse anti-PCNA (Abcam) and
were subsequently developed by Alexa Fluor 488 goat anti-guinea pig IgG
(H+L), Alexa Fluor 488 donkey anti-rabbit IgG (H+L), Alexa Fluor 488 donkey
anti-goat IgG (H+L), and/or Alexa Fluor 594 donkey anti-rat IgG (H+L), Alexa
Fluor 594 donkey anti-rabbit IgG (H+L), and Alexa Fluor 594 donkey anti-
mouse IgG (H+L) (Invitrogen). For DAB staining of the pancreatic b cells,
guinea pig anti-insulin antibody (Dako) and HRP-conjugated donkey anti-
guinea pig antibody (Jackson ImmunoResearch) were used and developed
by ImmPACT DAB kit (Vector Laboratories). For immunocytochemistry in
Hepa1-6 cells and immunofluorescence of m/hbetatrophin-Myc in liver after
hydrodynamic tail vein injection, cells or tissue cryosections were stained by
rabbit anti-Myc tag antibody (Abcam) and developed by Alexa Fluor 594
donkey anti-rabbit IgG (H+L). All cells and sections were mounted inoding GFP or betatrophin. Immunofluorescence of
). Note the absence of significant replication in the
immunohistochemistry (shown in brown).
ids (GFP, n = 5).
. n = 3 for the GFP group; n = 4 for the betatrophin
Sst+Ppy), exocrine cells, and duct cells, as well as
also Figures S2, S3, and S5.
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Vectorshield with DAPI (Vector Laboratories). Images were obtained using
Zeiss LSM510 confocal microscope, Olympus IX51 microscope, or Leica
MZ16FA microscope.
Quantifying Pancreatic b Cell Proliferation, Islet Size and Area,
Non-b Cell Proliferation, and Average b Cell Size
Whole-mouse pancreata were fixed and cryosectioned throughout. A series
of sections 300 mm apart were chosen for each set of experiments. For b cell
proliferation assays, sections were immunostained with anti-insulin and
anti-Ki67 antibody. For non-b cell pancreatic cell proliferation, sections
were immunostained with anti-amylase, anti-CK19, anti-somatostatin, anti-
glucagon, and anti-pancreatic polypeptide together with anti-Ki67 antibody.
Liver, white fat, and brown fat sections were immunostained with anti-Ki67
antibody. All islets were imaged, and total b cell number was counted by
counting nuclei surrounded by cytoplasmic insulin immunostaining, and the
proliferating b cells were assessed by counting nuclei stained with Ki67
within cytoplasmic insulin immunostaining. For each mouse, about 10,000
b cells were counted, and the b cell proliferation ratio was calculated by
dividing Ki67+ cell number by total b cell number. The non-b-cell pancreatic
cells and liver/fat cell proliferation rates were counted in a similar manner. For
islet size and b cell area quantification, the whole area for all sections was
imaged. The total pancreas area and insulin-positive area was selected using
Adobe Photoshop for each image. The total insulin-positive (b cell) area and
the average islet size (calculated from individual islet areas) were calculated
from these data for each mouse. The average b cell size was calculated by
dividing the total b cell area (insulin+ area) by the total b cell number from all
imaged islets.
Microarray and Real-Time PCR Analysis
b cells were purified from pancreata of Pdx1-GFP-transgenic mice after
infusion and digestion by collagenase P (Roche) by FACS. Total RNA
from various organs/tissues/cells was extracted using TRIzol (Invitrogen),
and genomic DNA was removed using QIAGEN RNeasy kit. For microarray
analysis, total RNA was amplified and biotin labeled using Illumina
TotalPrep RNA Amplification kit (Ambion). The cRNA was analyzed by
in-house Illumina BeadArray Reader and quantified using Illumina
BeadStudio. For real-time PCR analysis, cDNA was synthesized using
Superscript III First Strand cDNA synthesis kit (Invitrogen) and was analyzed
using an ABI 7900 system. The Taqman gene expression assays used
were mbetatrophin (Mm01175863_g1, Applied Biosystem), mActb
(Mm00607939_s1, Applied Biosystem), and hbetatrophin (Hs00218820_m1,
Applied Biosystem).
Cell-Cycle Genes and Transcript Profiling
Pancreatic islets were isolated after infusion and digestion of the pancreata by
collagenase P (Roche). The total RNA was immediately isolated from islets us-
ing an RNeasy mini kit (QIAGEN). The cDNA was synthesized using RT2 First
Strand Kit (QIAGEN), and quantitative PCR reactions were performed using
RT2 Profiler PCR Array Mouse Cell Cycle (QIAGEN).
DNA Transfection and Western Blotting
293T cell were transfected with GFP or betatrophin expression plasmids
using Lipofectamine 2000 Transfection Reagent (Invitrogen). Supernatants
were collected, filtered through 0.22 mm membrane, and concentrated 10
times using Amicon Ultra Centrifugation Filter with 10 kDa cutoff (Millipore).
The cell lysate was prepared using RIPA buffer (Santa Cruz) with protease
inhibitors. The liver lysate was prepared by homogenization in RIPA
buffer with protease inhibitors. For western blotting, the primary antibodies
used include rabbit anti-Myc-HRP antibody (Abcam), chicken anti-GFP
antibody (Aves Lab, Inc.), rabbit anti-GAPDH antibody (Abcam), and mouse
anti-TD26 antibody (Novus). The secondary antibodies used include HRP-
conjugated goat anti-rabbit IgG (H+L) (Jackson ImmunoResearch), HRP-
conjugated donkey anti-mouse IgG (H+L) (Jackson ImmunoResearch), and
HRP-conjugated donkey anti-chicken IgY (H+L) (Jackson ImmunoResearch).
The signal was developed using SuperSignal West Pico Chemiluminescent
Substrate (Pierce).756 Cell 153, 747–758, May 9, 2013 ª2013 Elsevier Inc.Hydrodynamic Tail Vein Injection
Seven-week-old male ICR mice (Taconic) were used for the hydrodynamic tail
vein injection for the ease of identifying the tail vein. The injections were per-
formed according to published methods (Liu et al., 1999; Song et al., 2002;
Yant et al., 2000; Zhang et al., 1999). 100 mg of GFP or betatrophin expression
plasmid DNA, controlled by either the CAG promoter or the EF1a promoter in
the sleeping beauty transposon backbone together with 4 mg of sleeping
beauty transposase expression plasmid (pCMV-SB100), were diluted in sterile
saline. The mice were anesthetized using avertin (250 mg/Kg) and were in-
jected with 8% of body weight volumes (ml/g) of diluted plasmid DNA within
5 to 7 s through the lateral tail veins. Glucose tolerance tests or insulin toler-
ance test were performed 6 days after injection, and the mice were sacrificed
8 days after injection for pancreatic b cell analysis.
Glucose Tolerance Test and Insulin Tolerance Test
Mice were fasted for 6 hr and then injected with 1 mg/g body weight of
D-glucose intraperitoneally. The blood glucose was measured from the tail
tip using One Touch Ultra 2 blood glucose meter (LifeScan, Inc.) at 0, 15, 30,
60, and 90 min postinjection. The area under curve is calculated using stan-
dard methods. For insulin tolerance tests, mice were not fasted and were in-
jected with 0.75 U/Kg of human insulin (Sigma) intraperitoneally. The blood
glucose was measured from the tail tip using One Touch Ultra 2 blood glucose
meter (LifeScan, Inc.) at 0, 30, and 60 min postinjection.
Insulin ELISA
Bloodwas collected after mice were sacrificed, and the plasmawas separated
according to standard protocols. Insulin ELISA assay was carried out with
Mouse Ultrasensitive Insulin ELISA Jumbo (ALPCO).
Statistics
All of the p values were calculated by a standard Student’s t test with two-tails
distribution.
ACCESSION NUMBERS
Microarray data were deposited in the Gene Expression Omnibus Database of
the National Centre for Biotechnology Information under the accession num-
ber GSE45694.
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